ArticleThe American journal of pathology2012
Nuclear Kaiso indicates aggressive prostate cancers and promotes migration and invasiveness of prostate cancer cells.
Article in The American journal of pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 64 citations in OpenAlex.
- The potential role of the gut microbiota in the development of autoantibodies associated with Spondyloarthritis: a narrative review.BMC immunology · 2026Review
- Kaiso modulates androgen receptor expression in triple-negative breast cancer.Breast cancer research : BCR · 2026Article
- Molecular Signature of Cisplatin Resistance in Ovarian Cancer Identifies Therapeutic Opportunities for Re-sensitization.Journal of Cancer · 2026Article
- When "One Size Fits All" Fits None: A Commentary on the Impacts of the"Draft Canadian Breast Cancer Screening Guidelines" on Racialized Populations in Canada.Current oncology (Toronto, Ont.) · 2025Review
- Association of Kaiso and partner proteins in oral squamous cell carcinoma.Journal of Taibah University Medical Sciences · 2023Article
- Immune Profile of Exosomes in African American Breast Cancer Patients Is Mediated by Kaiso/THBS1/CD47 Signaling.Cancers · 2023Article
- Kaiso Protein Expression Correlates with Overall Survival in TNBC Patients.Journal of clinical medicine · 2023Article
- Diagnostic value of anti-Kaiso autoantibody in axial spondyloarthritis.Frontiers in immunology · 2023Article
- Expressional variations of Kaiso: an association with pathological characteristics and field cancerization of OSCC.BMC cancer · 2022Article
- Kaiso phosphorylation at threonine 606 leads to its accumulation in the cytoplasm, reducing its transcriptional repression of the tumour suppressor CDH1.Molecular oncology · 2022Article
- Adherens junction proteins on the move-From the membrane to the nucleus in intestinal diseases.Frontiers in cell and developmental biology · 2022Review
- Molecular and Clinical Relevance ofCancers · 2020Article
- The pan-therapeutic resistance of disseminated tumor cells: Role of phenotypic plasticity and the metastatic microenvironment.Seminars in cancer biology · 2020Review
- Article
- Cancer as an Embryological Phenomenon and Its Developmental Pathways: A Hypothesis regarding the Contribution of the Noncanonical Wnt Pathway.TheScientificWorldJournal · 2019Review
- DNA Methylation Readers and Cancer: Mechanistic and Therapeutic Applications.Frontiers in oncology · 2019Review
- Kaiso-induced intestinal inflammation is preceded by diminished E-cadherin expression and intestinal integrity.PloS one · 2019Article
- Diversity in the Era of Precision Medicine - From Bench to Bedside Implementation.Ethnicity & disease · 2019Article
- Dancing from bottoms up - Roles of the POZ-ZF transcription factor Kaiso in Cancer.Biochimica et biophysica acta. Reviews on cancer · 2019Review
- The great escape: How metastases of melanoma, and other carcinomas, avoid elimination.Experimental biology and medicine (Maywood, N.J.) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
Kaiso, a p120 catenin-binding protein, is expressed in the cytoplasmic and nuclear compartments of cells; however, the biological consequences and clinical implications of a shift between these compartments have yet to be established. Herein, we report an enrichment of nuclear Kaiso expression in cells of primary and metastatic prostate tumors relative to the normal prostate epithelium. Nuclear expression of Kaiso correlates with Gleason score (P < 0.001) and tumor grade (P < 0.001). There is higher nuclear expression of Kaiso in primary tumor/normal matched samples and in primary tumors from African American men (P < 0.0001). We further found that epidermal growth factor (EGF) receptor up-regulates Kaiso at the RNA and protein levels in prostate cancer cell lines, but more interestingly causes a shift of cytoplasmic Kaiso to the nucleus that is reversed by the EGF receptor-specific kinase inhibitor, PD153035. In both DU-145 and PC-3 prostate cancer cell lines, Kaiso inhibition (short hairpin RNA-Kaiso) decreased cell migration and invasion even in the presence of EGF. Further, Kaiso directly binds to the E-cadherin promoter, and inhibition of Kaiso in PC-3 cells results in increased E-cadherin expression, as well as re-establishment of cell-cell contacts. In addition, Kaiso-depleted cells show more epithelial morphology and a reversal of the mesenchymal markers N-cadherin and fibronectin. Our findings establish a defined oncogenic role of Kaiso in promoting the progression of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.